Montreal, Quebec–(Newsfile Corp. – December 10, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the […]

Rimouski, Quebec–(Newsfile Corp. – December 10, 2025) – Puma Exploration Inc. (TSXV: PUMA) (OTCQB: PUMXF) (the “Company” or “Puma”) announces that it has closed a non-brokered placement (the “FT Private Placement”) consisting of 6,000,000 flow-through units (the “FT Units”) at $0.20 per FT Unit for gross proceeds of C$1,200,000. Each FT Unit comprises one flow-through

Vancouver, British Columbia–(Newsfile Corp. – December 10, 2025) – Intrepid Metals Corp. (TSXV: INTR) (OTCQB: IMTCF) (“Intrepid” or the “Company”) announces that the Company intends to extend the exercise period of a total of 19,046,764 share purchase warrants, all of which are exercisable at $0.45 per common share (collectively, the “Warrants”) by 90 days. The

Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,284,404 shares of its common stock at

Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, will announce its financial results for the fourth quarter of 2025 before the market opens on Friday, February 6, 2026. A conference call with remarks by the company's senior management will begin at 7:30 a.m. CT (8:30 a.m. ET). https://mma.prnewswire.com/media/622233/Cboe_GM_New_Logo.jpg A

(NYSE MKT:SER), – Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback HUNTSVILLE, Dec. 10, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead

(NASDAQ:SERV),(NYSE:UBER), ALEXANDRIA, Va., Dec. 10, 2025 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leading autonomous sidewalk delivery company, and the City of Alexandria today announced the launch of Serve's on-demand robotic delivery service in Alexandria, Virginia. In partnership with Uber Eats, the delivery-platform of Uber Technologies (NYSE: UBER), residents and businesses in North

(NasdaqGM:NBP), Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance The study achieved its objective, as the new Q6W extended dosing interval produced encouraging

(NASDAQ:DSAC),(NASDAQ:DSACW),(NASDAQ:DSACU), London, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) — Daedalus Special Acquisition Corp. (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Co-Chief Executive Officers Husnu Akin Babayigit and Orkun Kilic, today announced the closing of its upsized pricing of its initial public offering

(TSX:EIT-UN),(TSX:EIT.UN),(TSX:EIT-PA),(TSX:EIT-PB), CALGARY, Alberta, Dec. 10, 2025 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (“Canoe” or the “Fund”)(TSX – EIT.UN) today announced that units accepted for the 2025 voluntary cash redemption will be redeemed at a price of $15.36 per unit (rounded) in Canadian dollars. This price is equal to 95% of the average net asset